News
Plexus Ventures Assists Laboratorios Cinfa in Selling Biosimilar Business to Mundipharma
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a divestiture project for its client, Laboratorios Cinfa, S.A. of Pamplona, Spain. Plexus Ventures advised Cinfa on the sale of its biosimilar business, Cinfa Biotech to a...
Mabion S.A. completes marketing authorization application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)
Plexus Ventures would like to share successful news from Mabion S.A. Additional details are provided in Mabion’s press release (Konstantynów Łódzki, 1.06.2018): • Company submitted the marketing authorization application under the centralized authorization procedure...
Plexus Ventures Assists Fujifilm Kyowa Kirin Biologics in Partnering with Mylan of Humira® Biosimilar
Tokyo, Japan – Plexus Ventures is pleased to announce the successful conclusion of an out-licensing project of its client Fujifilm Kyowa Kirin Biologics Co., Ltd. Plexus Ventures provided professional services to Fujifilm Kyowa Kirin Biologics to partner the European...
Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex® on Scandinavian markets
Plexus Ventures would like to share successful news from Celon Pharma. Additional details are provided in Celon’s press release (Warsaw, 30.11.2017): • Finalisation of the DCP opens new perspectives for the Company in terms of export to the market as big as approx. 3...
Plexus Ventures Assists Celon Pharma SA with Development Strategy
Philadelphia, PA - Plexus Ventures, a global pharmaceutical consulting firm, announces its collaboration with Celon Pharma SA, Łomianki, Poland. Michael O’Sullivan Managing Partner London Office, noted: “We are very pleased to provide continuing support to an...
Plexus Ventures Assists Sylphar with Vendis Capital Investment, Enabling Concordia Fund Exit
Philadelphia, Pennsylvania - Plexus Ventures is pleased to announce it assisted the successful completion of a transaction in which Vendis Capital, a European private equity fund specialized in the consumer brands sector, invested in Sylphar, a fast-growing, Belgian...
Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Valeas S.p.A. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This agreement allows Valeas to extend its...
Plexus Ventures Announces Team Promotions
Philadelphia, Pennsylvania – Plexus Ventures, a prominent corporate and business development boutique for healthcare companies, is pleased to announce two promotions among its team members.Gabriele Tundo, Vice President, has been promoted to Partner. Gabriele joined...
Articles
Nucleic acid delivery: Are you developing what Big Pharma seeks?
Apr 11, 2023
How can we help you?
Plexus Ventures assists with M&A, divestments, licensing, strategic advice and consulting.
Subscribe to
Plexus News
Follow Us
Check out Plexus Ventures and other industry news shared daily.